Susceptibility of various mouse strains to systemically- or aerosol-initiated tularemia by virulent type A Francisella tularensis before and after immunization with the attenuated live vaccine strain of the pathogen.

A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infect Immun (2005) 2.53

Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS. Infect Immun (2006) 1.93

Attenuated Francisella novicida transposon mutants protect mice against wild-type challenge. Infect Immun (2006) 1.73

Identification of genes contributing to the virulence of Francisella tularensis SCHU S4 in a mouse intradermal infection model. PLoS One (2009) 1.58

AcpA is a Francisella acid phosphatase that affects intramacrophage survival and virulence. Infect Immun (2006) 1.39

An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine (2008) 1.35

Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect Immun (2008) 1.31

Virulence comparison in mice of distinct isolates of type A Francisella tularensis. Microb Pathog (2006) 1.28

Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody. Vaccine (2008) 1.19

Molecular immunology of experimental primary tularemia in mice infected by respiratory or intradermal routes with type A Francisella tularensis. Mol Immunol (2008) 1.16

Identification of immunologic and pathologic parameters of death versus survival in respiratory tularemia. Infect Immun (2007) 1.15

Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin Vaccine Immunol (2009) 1.12

Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization. Vaccine (2009) 1.11

Francisella tularensis reveals a disparity between human and mouse NLRP3 inflammasome activation. J Biol Chem (2011) 1.07

Directed screen of Francisella novicida virulence determinants using Drosophila melanogaster. Infect Immun (2010) 1.04

Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge. Vaccine (2009) 1.03

Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains. Vaccine (2009) 0.98

Development of functional and molecular correlates of vaccine-induced protection for a model intracellular pathogen, F. tularensis LVS. PLoS Pathog (2012) 0.96

Infection of mice with Francisella as an immunological model. Curr Protoc Immunol (2011) 0.96

Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS). PLoS One (2010) 0.92

Cyclic di-GMP stimulates biofilm formation and inhibits virulence of Francisella novicida. Infect Immun (2012) 0.89

Francisella inhibits STAT1-mediated signaling in macrophages and prevents activation of antigen-specific T cells. Int Immunol (2008) 0.88

Successful protection against tularemia in C57BL/6 mice is correlated with expansion of Francisella tularensis-specific effector T cells. Clin Vaccine Immunol (2014) 0.87

Models derived from in vitro analyses of spleen, liver, and lung leukocyte functions predict vaccine efficacy against the Francisella tularensis Live Vaccine Strain (LVS). MBio (2014) 0.83

Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4. Vaccine (2010) 0.82

Protective immunity against tularemia provided by an adenovirus-vectored vaccine expressing Tul4 of Francisella tularensis. Clin Vaccine Immunol (2012) 0.80

Respiratory infection with Francisella novicida induces rapid dystrophic cardiac calcinosis (DCC). FEMS Immunol Med Microbiol (2008) 0.77

Efficacy of Resistance to Francisella Imparted by ITY/NRAMP/SLC11A1 Depends on Route of Infection. Front Immunol (2017) 0.75

The Natural History of Pneumonic Tularemia in Female Fischer 344 Rats after Inhalational Exposure to Aerosolized Francisella tularensis Subspecies tularensis Strain SCHU S4. Am J Pathol (2016) 0.75

F. novicida-Infected A. castellanii Does Not Enhance Bacterial Virulence in Mice. Front Cell Infect Microbiol (2016) 0.75

Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology (2002) 5.50

Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb Pathog (2003) 2.61

A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infect Immun (2005) 2.53

Structural analysis of Francisella tularensis lipopolysaccharide. Eur J Biochem (2002) 2.33

Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine (2003) 1.98

Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism. Vaccine (2005) 1.84

Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect Immun (2007) 1.77

Distinct roles of reactive nitrogen and oxygen species to control infection with the facultative intracellular bacterium Francisella tularensis. Infect Immun (2004) 1.61

Susceptibility of immunodeficient mice to aerosol and systemic infection with virulent strains of Francisella tularensis. Microb Pathog (2004) 1.50

Fibrin-mediated protection against infection-stimulated immunopathology. J Exp Med (2003) 1.43

Transcriptional profiling of host responses in mouse lungs following aerosol infection with type A Francisella tularensis. J Med Microbiol (2006) 1.29

Virulence comparison in mice of distinct isolates of type A Francisella tularensis. Microb Pathog (2006) 1.28

A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity. Infect Immun (2007) 1.27

Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis. Vaccine (2007) 1.24

Anti-CD25 antibody-mediated depletion of effector T cell populations enhances susceptibility of mice to acute but not chronic Toxoplasma gondii infection. J Immunol (2009) 1.22

Molecular immunology of experimental primary tularemia in mice infected by respiratory or intradermal routes with type A Francisella tularensis. Mol Immunol (2008) 1.16

Toll-like receptor 4 (TLR4) does not confer a resistance advantage on mice against low-dose aerosol infection with virulent type A Francisella tularensis. Microb Pathog (2004) 1.15

Infection-stimulated fibrin deposition controls hemorrhage and limits hepatic bacterial growth during listeriosis. Infect Immun (2005) 1.15

Toll-like receptor 4 (TLR4) plays a relatively minor role in murine defense against primary intradermal infection with Francisella tularensis LVS. Immunol Lett (2005) 1.14

Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy. PLoS One (2010) 1.13

Role of macrophages in early host resistance to respiratory Acinetobacter baumannii infection. PLoS One (2012) 1.12

Low dose aerosol infection of mice with virulent type A Francisella tularensis induces severe thymus atrophy and CD4+CD8+ thymocyte depletion. Microb Pathog (2005) 1.12

Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization. Vaccine (2009) 1.11

High susceptibility to respiratory Acinetobacter baumannii infection in A/J mice is associated with a delay in early pulmonary recruitment of neutrophils. Microbes Infect (2009) 1.07

Role of Toll-like receptors in health and diseases of gastrointestinal tract. World J Gastroenterol (2006) 1.06

Intestinal M cells: the fallible sentinels? World J Gastroenterol (2007) 1.05

In vitro and in vivo biological activities of iron chelators and gallium nitrate against Acinetobacter baumannii. Antimicrob Agents Chemother (2012) 1.04

Mice sublethally infected with Francisella novicida U112 develop only marginal protective immunity against systemic or aerosol challenge with virulent type A or B strains of F. tularensis. Microb Pathog (2004) 1.04

Role of NADPH phagocyte oxidase in host defense against acute respiratory Acinetobacter baumannii infection in mice. Infect Immun (2008) 1.04

Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis. Vaccine (2008) 1.04

BALB/c mice, but not C57BL/6 mice immunized with a ΔclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses. Vaccine (2012) 1.02

Francisella tularensis proteome: low levels of ASB-14 facilitate the visualization of membrane proteins in total protein extracts. J Proteome Res (2005) 1.01

Correlates of protection following vaccination of mice with gene deletion mutants of Francisella tularensis subspecies tularensis strain, SCHU S4 that elicit varying degrees of immunity to systemic and respiratory challenge with wild-type bacteria. Mol Immunol (2012) 1.00

Immunoproteomic analysis of the murine antibody response to successful and failed immunization with live anti-Francisella vaccines. Biochem Biophys Res Commun (2006) 0.99

3',5'-Cyclic diguanylic acid: a small nucleotide that makes big impacts. Chem Soc Rev (2010) 0.98

Exacerbated susceptibility to infection-stimulated immunopathology in CD1d-deficient mice. J Immunol (2005) 0.97

Role of neutrophils and NADPH phagocyte oxidase in host defense against respiratory infection with virulent Francisella tularensis in mice. Microbes Infect (2011) 0.97

Infection of mice with Francisella as an immunological model. Curr Protoc Immunol (2011) 0.96

Methylamidation for sialoglycomics by MALDI-MS: a facile derivatization strategy for both α2,3- and α2,6-linked sialic acids. Anal Chem (2010) 0.95

M cell-targeted delivery of vaccines and therapeutics. Expert Opin Drug Deliv (2008) 0.94

Vaccination protects B cell-deficient mice against an oral challenge with mildly virulent Toxoplasma gondii. Vaccine (2004) 0.94

A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain. Antimicrob Agents Chemother (2013) 0.94

Measurement of macrophage-mediated killing of intracellular bacteria, including Francisella and mycobacteria. Curr Protoc Immunol (2011) 0.93

Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS). PLoS One (2010) 0.92

Modulation of toxin production by the flagellar regulon in Clostridium difficile. Infect Immun (2012) 0.92

Acinetobacter baumannii infection inhibits airway eosinophilia and lung pathology in a mouse model of allergic asthma. PLoS One (2011) 0.90

Differential susceptibility of Sprague-Dawley and Fischer 344 rats to infection by Francisella tularensis. Microb Pathog (2009) 0.90

Chemical synthesis and immunological evaluation of the inner core oligosaccharide of Francisella tularensis. J Am Chem Soc (2012) 0.89

3',5'-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection. Biochem Biophys Res Commun (2009) 0.88

Production of a D-glycero-D-manno-heptosyltransferase mutant of Mannheimia haemolytica displaying a veterinary pathogen specific conserved LPS structure; development and functionality of antibodies to this LPS structure. Vet Microbiol (2006) 0.88

Identification of a D-glycero-D-manno-heptosyltransferase gene from Helicobacter pylori. J Bacteriol (2005) 0.83

Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Vaccine (2007) 0.83

Synthesis and immunostimulatory properties of the phosphorothioate analogues of cdiGMP. Bioorg Med Chem Lett (2008) 0.83

Archaeal lipid mucosal vaccine adjuvant and delivery system. Expert Rev Vaccines (2010) 0.82

Profiling of cytokine and chemokine responses using multiplex bead array technology. Methods Mol Biol (2013) 0.81

Francisella tularensis: a red-blooded pathogen. J Infect Dis (2011) 0.81

c-di-GMP protects against intranasal Acinetobacter baumannii infection in mice by chemokine induction and enhanced neutrophil recruitment. Int Immunopharmacol (2011) 0.81

The structure of the polysaccharide O-chain of the LPS from Acinetobacter baumannii strain ATCC 17961. Carbohydr Res (2009) 0.80

A novel pentamer versus pentamer approach to generating neutralizers of verotoxin 1. Mol Immunol (2006) 0.78

Pentabody-mediated antigen delivery induces antigen-specific mucosal immune response. Mol Immunol (2009) 0.78

Safety of intranasally administered archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) vaccine in mice. Int J Toxicol (2008) 0.78

Lymphotoxin-alpha plays only a minor role in host resistance to respiratory infection with virulent type A Francisella tularensis in mice. Mediators Inflamm (2008) 0.78

Intranasal immunization with an archaeal lipid mucosal vaccine adjuvant and delivery formulation protects against a respiratory pathogen challenge. PLoS One (2010) 0.77

Structural characterization of archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) formulations prepared by different protocols and their efficacy upon intranasal immunization of mice. J Liposome Res (2008) 0.77

Design and immunological properties of Helicobacter pylori glycoconjugates based on a truncated lipopolysaccharide lacking Lewis antigen and comprising an α-1,6-glucan chain. Vaccine (2012) 0.77

Simultaneous analysis of cardiolipin and lipid A from Helicobacter pylori by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Mol Biosyst (2012) 0.76

Archaeosomes as adjuvants for combination vaccines. J Liposome Res (2004) 0.75

Safety evaluation of calcium administered intranasally to mice. Int J Toxicol (2009) 0.75

Archaeosome immunostimulatory vaccine delivery system. Curr Drug Deliv (2005) 0.75